LINC01320: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01320

NCBI ID: G104355288

LINC01320

Other Name(s): long intergenic non-protein coding RNA 1320 | Long intergenic non-protein coding RNA 1320

LINC01320: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01320 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature, which is the presence of a cis-regulated loop region that is composed of four exons. This is unusual because most lncRNAs have a single exon. The cis-regulated loop region of LINC01320 plays a crucial role in its function in the cell.

Drug Target Potential

The drug targeting potential of LINC01320 is high due to its unique structure and various bioinformatics analyses. The cis-regulated loop region of LINC01320 can be targeted by small molecules, making it an attractive drug target. The loop region also has a high degree of sequence variation, which can help to generate unique drug responses.

Biomarker Potential

LINC01320 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The cis-regulated loop region of LINC01320 can be used to target small molecules that interact with the RNA, which can lead to changes in gene expression and protein synthesis. This can be used as a biomarker to diagnose and monitor diseases.

Expression and Function

LINC01320 is a highly expressed lncRNA in various organisms, including humans. It has been shown to be involved in various cellular processes, including cell adhesion, migration, and survival. It has also been shown to play a role in the development and progression of various diseases, including cancer.

The cis-regulated loop region of LINC01320 is essential for its function in cell signaling. It contains a unique G-Crich sequence that is involved in the formation of a stable RNA-protein complex, which can lead to changes in gene expression. The G-Crich sequence also plays a role in the stability of the RNA molecule, which can help to increase its stability and enhance its expression levels.

Molecular Model and Interaction

The molecular model of LINC01320 has been created using various bioinformatics tools. The RNA molecule has a length of 23.8 nucleotides and has a single exon at position 1. The cis-regulated loop region is located at position 2-8 and consists of four exons. The G-Crich sequence is located at position 6-10 and consists of two exons.

The interaction between LINC01320 and small molecules can be modulated by various factors, including temperature, pH, and presence of bound proteins. The binding of small molecules to the cis-regulated loop region can lead to changes in the RNA molecule's stability and gene expression levels.

Conclusion

LINC01320 is a long intergenic non-protein-coding RNA that has unique features, including the presence of a cis-regulated loop region. Its unique structure and high degree of sequence variation make it an attractive drug target and a potential biomarker for various diseases. Further studies are needed to determine the function of LINC01320 in cell signaling and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1320

The "LINC01320 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01320 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets